Production (Stage)
Ikena Oncology, Inc.
IKNA
$1.43
$0.064.38%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -95.28% | -90.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -95.28% | -90.38% |
| Cost of Revenue | -61.11% | -70.60% | -63.45% | -48.13% | -39.32% |
| Gross Profit | 59.17% | 68.28% | 56.69% | 33.86% | 17.60% |
| SG&A Expenses | -12.49% | -9.06% | -5.00% | 13.08% | 22.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -43.85% | -39.20% | -35.50% | -21.35% | -14.07% |
| Operating Income | 42.42% | 36.11% | 27.66% | 6.32% | -7.76% |
| Income Before Tax | 54.12% | 40.83% | 28.17% | 4.96% | -6.39% |
| Income Tax Expenses | 245.21% | 213.33% | 193.83% | -- | -- |
| Earnings from Continuing Operations | 53.91% | 40.50% | 27.77% | 5.06% | -6.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 53.91% | 40.50% | 27.77% | 5.06% | -6.28% |
| EBIT | 42.42% | 36.11% | 27.66% | 6.32% | -7.76% |
| EBITDA | 42.22% | 35.72% | 27.33% | 6.08% | -7.92% |
| EPS Basic | 55.31% | 45.18% | 37.57% | 23.37% | 15.89% |
| Normalized Basic EPS | 57.70% | 47.99% | 43.47% | 28.51% | 19.80% |
| EPS Diluted | 55.31% | 45.18% | 37.57% | 23.37% | 15.89% |
| Normalized Diluted EPS | 57.70% | 47.99% | 43.47% | 28.51% | 19.80% |
| Average Basic Shares Outstanding | 2.77% | 7.92% | 15.68% | 24.09% | 26.85% |
| Average Diluted Shares Outstanding | 2.77% | 7.92% | 15.68% | 24.09% | 26.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |